Cargando…

Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data

This letter highlights a rare association of anti-HER2 cancer therapy with development of pulmonary arterial hypertension, based on a review of data from the FDA https://bit.ly/2X90xDu

Detalles Bibliográficos
Autores principales:	Umoru, Godsfavour, Taitano, Matthew, Beshay, Sarah, Niravath, Polly, Sahay, Sandeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Original Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369436/ https://www.ncbi.nlm.nih.gov/pubmed/32714960 http://dx.doi.org/10.1183/23120541.00199-2020

Ejemplares similares

Evaluation, Diagnosis, and Classification of Pulmonary Hypertension
por: Sarah, Beshay, et al.
Publicado: (2021)

Progression of pulmonary veno‐occlusive disease without pulmonary hypertension
por: Beshay, Sarah, et al.
Publicado: (2022)

E‐REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension
por: Sahay, Sandeep, et al.
Publicado: (2022)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
por: Allen, Emily, et al.
Publicado: (2023)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

An adult case of NOTCH3 mutation in pulmonary artery hypertension
por: Padhye, Akhilesh A., et al.
Publicado: (2022)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Management of hospitalized patients with pulmonary arterial hypertension and COVID-19 infection
por: Sahay, Sandeep, et al.
Publicado: (2020)

Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
por: Makunts, Tigran, et al.
Publicado: (2023)

Palliative care in pulmonary arterial hypertension: an underutilised treatment
por: Khirfan, Ghaleb, et al.
Publicado: (2018)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Insulin‐like growth factor binding protein‐4: The quest for the breakthrough biomarker in pulmonary arterial hypertension
por: Estrada, Rodolfo A., et al.
Publicado: (2023)

The cascade screening in heritable forms of pulmonary arterial hypertension
por: Varghese, Nidhy P., et al.
Publicado: (2023)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature
por: Chatham, Mathew, et al.
Publicado: (2021)

Insights and Advances in the Diagnosis, Treatment, and Management of Pulmonary Hypertension
por: Guha, Ashrith, et al.
Publicado: (2021)

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Picken, Christina, et al.
Publicado: (2019)

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Buck, Benjamin, et al.
Publicado: (2022)

Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
por: Sahay, Sandeep, et al.
Publicado: (2020)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Drs. Sandeep Sahay and Ashrith Guha Lead Issue on Pulmonary Hypertension
por: Sahay, Sandeep, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qpdjr282kibp1kbmuo8f1ijqjb